Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18649030 | 0.89 | HTR1D (0.36) | NPC1RAB9ALMNAMAPK1CASP3 | |
| SCHEMBL17987324 | 0.89 | NPC1 (0.34) | NPC1RAB9ALMNAMAPK1CASP3 | |
| SCHEMBL18649031 | 0.87 | NPC1 (0.33) | NPC1RAB9ALMNAMAPK1CASP3 | |
| SCHEMBL17552740 | 0.84 | RIPK1 (0.40) | NPC1RAB9ALMNAMAPK1CASP3 | |
| SCHEMBL17552749 | 0.84 | RIPK1 (0.44) | RIPK1 | |
| SCHEMBL17552753 | 0.82 | RIPK1 (0.33) | RIPK1 | |
| SCHEMBL13918213 | 0.81 | NR1H2 (0.37) | RIPK1PDE2A | |
| SCHEMBL13918218 | 0.80 | ESR1 (0.39) | NPC1RAB9ALMNAMAPK1CASP3 | |
| SCHEMBL780091 | 0.77 | NPC1 (0.43) | NPC1RAB9ALMNAMAPK1CASP3 | |
| SCHEMBL21849062 | 0.77 | RARG (0.36) | NPC1RAB9ALMNAMAPK1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180021316-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-01-25 | — | — | US | disclosed |
| US-9598639-B2 | Liquid-crystal compound, liquid-crystal composition and liquid-crystal display device | DAXIN MATERIALS CORPORATION (TW) | 2017-03-21 | — | — | US | disclosed |
| US-20160024384-A1 | LIQUID-CRYSTAL COMPOUND, LIQUID-CRYSTAL COMPOSITION AND LIQUID-CRYSTAL DISPLAY DEVICE | DAXIN MATERIALS CORPORATION (TW) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021316-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, TP53 | NPC1 273/4885RAB9A 1663/4885LMNA 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.